Newly available Injectable, Xeomin® Hits Shelves
The JUVA Skin & Laser Center, New York‘s premier destination for the most advanced skin and laser treatments, will be among the first 100 dermatology offices in the US to receive Xeomin® (incobotulinumtoxinA) for cosmetic use beginning October 2011.
Xeomin®, a Merz Aesthetics product, is being referred to as the “naked injectable” by physicians because it does not contain any additives or complex proteins. The benefit of this, according to Dr. Bruce Katz, Clinical Professor of Dermatology at The Mount Sinai School of Medicine and Director of the JUVA Skin & Laser Center in New York, is that the body is less likely to have an adverse reaction to the treatment than with Botox®. Side effects and efficacy are expected to be similar to other botulinum toxin products.
“We are thrilled to have another highly effective botulinum toxin available to treat frown lines – which is still one of the most commonly treated areas here at JUVA,” said Dr. Bruce Katz. “By being selected to offer this cutting edge product to our clients as early as possible the JUVA Skin & Laser Center is once again at the forefront of the latest advancements in skin treatment. We expect that the availability of Xeomin® will offer even more safety assurance to patients opting for this type of an injectable treatment and ultimately create some friendly price competition among its competitors.”
Xeomin® was approved by the United States Food and Drug Administration (FDA) in July for the temporary improvement in the appearance of moderate to severe glabellar lines, more commonly known as frown lines between the eyebrows, in adult patients. This approval was based on two clinical trials that found that Xeomin® significantly improved the appearance of glabellar lines 30 days following the first injection.
Xeomin® will be available in dermatology offices around the United States in the spring of 2012; however, JUVA Skin & Laser Center will be offering the treatment as early as November 2011. It is also approved for the improvement of glabellar lines in 14 countries in Europe under the brand name Bocouture.
Short URL: http://www.plasticsurgeonsnews.com/?p=1301